2026 FDA Labeling Guidance Requires Changes, Packaging Tips for Bath Bomb Sellers
New FDA draft guidance and MoCRA-era rules mean small bath‑bomb sellers who market products as cosmetics must register facilities, list products, update labels to INCI and US units, and prepare records access.
1. facility registration and product listing under mocra
MoCRA makes registration and product listing mandatory for cosmetic manufacturing facilities and their products; Esko’s practical guide (published February 16, 2026) emphasizes how this affects small makers and sellers in 2026. The haircare FAQ is explicit: “Is FDA registration mandatory for private label haircare? Yes. Under MoCRA, cosmetic manufacturing facilities must register with the FDA, and each haircare product must be listed, even for private label products.” Treat registration and listing as immediate operational tasks, confirm the responsible person for each SKU and document registration numbers in your quality files.
2. required label elements every cosmetic label must include
FDA sources list the core elements: product identity; net contents with US customary units required; ingredient list using INCI names; manufacturer or distributor information; proper warnings if applicable; and all required information must appear in English. These are not negotiable checklist items, Esko’s synthesis and the FDA haircare compilation show that missing any of these fields invites enforcement; “Labeling is one of the most common reasons haircare products are stopped at the border.” Use this list as a template when updating artwork and pressure‑sensitive labels.
3. ingredient declaration conspicuousness and type‑size rules (21 CFR 701.3)
Follow the explicit typographic rules in 21 CFR 701.3: ingredient declarations must be conspicuous and likely to be read at purchase; letter heights must not be less than 1/16 inch (21 CFR 701.3(b)), and if the package surface available to bear labeling is less than 12 square inches, letters must not be less than 1/32 inch (21 CFR 701.3(p)). Off‑package ingredient labeling is permitted only under the conditions in 21 CFR 701.3(i) (for tightly compartmented trays/racks, no folding carton, and package surface area < 12 sq. in.). Make sure proofs measure letter heights on the actual substrate and that your supplier signs off to avoid non‑compliance.
4. tamper‑resistant packaging: when it applies and what counts
FDA requires tamper‑resistant retail packaging for liquid oral hygiene products and all cosmetic vaginal products, and defines tamper resistance with examples: shrink or tape seal, sealed carton, tube or pouch, aerosol container. The agency explains the indicator must be “distinctive by design (breakable cap, blister) or appearance (logo, vignette, other illustration) to preclude substitution,” and the package must bear a prominently placed statement alerting the consumer to the tamper‑resistant feature. While bath bombs aren’t named in these examples, if you sell any product lines that fit those categories, adopt tamper‑resistant features and prominently word the consumer alert per the FDA text.
5. draft “records access” guidance and what to expect during inspections
The FDA’s draft guidance titled “FDA Records Access Authority for Cosmetics: Guidance for Industry” was released January 22, 2026 (91 FR 2779; FR Doc. 2026‑01159; Docket No. FDA‑2025‑D‑2243) and was filed on public inspection 01/21/2026 at 8:45 am (viewed 90 times while on Public Inspection). Wiley Law summarizes: “The U.S. Food and Drug Administration (FDA) has issued a draft guidance reminding the cosmetics industry that the agency can access a variety of business records during an inspection of a product’s responsible person and manufacturing/processing facility.” The draft explains FDA’s legal authority to access and copy records, and notes that “the refusal to permit access to or copying of such records is a prohibited act under the Federal Food, Drug, and Cosmetic Act (FD&C Act).” The draft was developed by FDA’s Office of Inspections and Investigations in collaboration with the Office of the Chief Scientist. Comments on the draft guidance are due March 23, 2026; as the Federal Register text instructs, “Submit either electronic or written comments on the draft guidance by March 23, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.”
6. trade secrets, data protection, and recordkeeping assurances
Wiley Law notes the guidance “describes FDA’s legal authority for accessing and copying these records, which often contain confidential business information,” and that “FDA confirms that it will protect a company’s trade secrets as well as personal privacy information, and will guard against the unauthorized disclosure of non‑public information.” That reassurance does not remove the obligation to make records accessible; prepare a redaction plan for legitimately confidential fields, a records index for inspectors, and clear internal procedures so refusal is never on the table.
7. avoid drug claims and protect private‑label relationships
Watch claims closely: the haircare FAQ warns, “If a haircare product claims to treat or prevent hair or scalp conditions, the FDA may regulate it as an OTC drug.” The note “👉 This is one of the most common risks for overseas brands entering the US market” is a real risk signal for private‑label sellers. Review product copy on listings, labels, and marketing to remove any treatment/prevention language unless you intend to follow OTC drug pathways. As one guidance line puts it bluntly for buyers: “Choosing the wrong manufacturer increases legal, customs, and brand risk.”
- Substantiate claims with documentation and keep the evidence in your regulatory folder.
- Separate the logistics team’s shipping‑label template from the design team’s consumer label artwork.
- Put a regulatory sign‑off step into every SKU launch and work with experienced packaging partners, as Esko’s guide recommends.
8. packaging and labeling best practices from industry advisers
Packaging strategist Haley Seiberlich recommends a proactive compliance approach: “Always have reliable evidence to support any claims made on your product labels” and “Regularly review FTC guidelines and updates to ensure ongoing compliance.” Her material (last updated January 14, 2026) also suggests “Consider integrating RFID labels into your packaging strategy to improve product tracking and enhance consumer trust.” Meyers adds operational clarity: “Shipping labels and packaging labels may serve different purposes, but both must be accurate and compliant. Shipping labels often include logistics and handling information, while packaging labels focus on consumer-facing requirements.” Practical steps:
9. state‑level rules, timing, and the 2026 competitive reality
Don’t stop at federal boxes, Sevich notes that “Many US states (such as California) may apply additional restrictions, making compliance even more important.” Build a compliance calendar: Esko’s February 16, 2026 guide followed the FDA’s January draft; Wiley Law’s alert was published February 2, 2026; the Federal Register shows the public filing as FR Doc. 2026‑01159. Treat these developments as a near‑term operating shift: “The Modernization of Cosmetics Regulation Act (MoCRA) is the biggest change in US cosmetic regulation in decades,” and “MoCRA significantly expands FDA enforcement power.” Final takeaway: “In 2026, FDA compliance is no longer just a legal detail, it is a competitive advantage.” For haircare brands and B2B buyers, “working with a MoCRA‑ready, FDA‑compliant manufacturer is one of the most effective ways to protect your business in the US market.” Follow the deadlines, measure your labels against 21 CFR 701.3, confirm registration/listing, and prepare records access procedures now, those steps convert regulatory risk into business resilience.
Know something we missed? Have a correction or additional information?
Submit a Tip
